Guardant Health (GH) announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield test. The agreement was set up through Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, and will be administered by the M42 healthcare system.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Netflix upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
- Guardant Health initiated with an Overweight at Barclays
- Guardant Health price target raised to $55 from $50 at BTIG
- Guardant Health: MolDX administrator grants coverage for Guardant Reveal
- Guardant Health, ConcertAI team for RWD that integrates EMR data for cancer care